

# Anti-PCSK9 (Alirocumab), Human IgG1 Antibody

06/20

---

**CATALOG NO.:** A2153-100 (100 µg)
 

---

**BACKGROUND DESCRIPTION:** The research-grade biosimilar antibody is a fully human IgG1 monoclonal antibody that binds to and inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), an enzyme that has "gain-of-function" mutations in autosomal dominant hypercholesterolemia. PCSK9 is secreted by the liver and binds to the LDL receptors in serum and marks them for lysosomal degradation. As a result, the LDL receptors are unable to recycle to the plasma membrane, thus reducing their binding to LDL-C and subsequent clearance of LDL-C from plasma. Therefore, by binding to free PCSK9, the biosimilar allows more LDL-C reuptake by the liver and facilitates a higher rate of clearance of LDL-C. The original drug received approval from the FDA as a second-line of treatment for heterozygous familial hypercholesterolemia in adults, who's LDL-C cannot controlled by the combination of diet and statin treatment.

**ALTERNATE NAMES:** REGN727, SAR-236553, FH3; PC9; FHCL3; NARC1; LDLCQ1; NARC-1; HCHOLA3

**ANTIBODY TYPE:** Monoclonal

**CONCENTRATION:** 1 mg/ml

**HOST/ISOTYPE:** Recombinant / IgG1, kappa

**SOURCE:** CHO cells

**IMMUNOGEN:** Human PCSK9

**MOLECULAR WEIGHT:** 146 kDa

**PURIFICATION:** Protein A purified

**FORM:** Liquid

**FORMULATION:** In PBS, pH 7.5

**SPECIES REACTIVITY:** Human

**STORAGE CONDITIONS:** Store at -80°C

**This information is only intended as a guide. The optimal dilutions must be determined by the user**

**RELATED PRODUCTS:**

Anti-IL-12 $\beta$  (Ustekinumab), Human IgG1 Antibody (A2137)  
 Anti-TNF- $\alpha$  (Certolizumab Pegol), Humanized Antibody (A2142)  
 Anti-TNF- $\alpha$  (Adalimumab), humanized Antibody (A1048)  
 Anti-IL-6 (Siltuximab), Chimeric Antibody (A2143)  
 Anti-TNF alpha (Infliximab), Human IgG1 Antibody (A1097)

**FOR RESEARCH USE ONLY! Not to be used on humans.**